Startups channel feed – Endpoints News

Startups channel feed

Money, brains and ambition: Third Rock startup Tango launches with $55M and a stellar crew of scientific advisers

9 years ago

Novartis research leader takes the helm at Forty Seven, a CIRM-backed fledgling already deep in the clinic

9 years ago

Google’s venture arm leads Spero’s $51.7M round for R&D work on a pipeline of new antibiotics

9 years ago

High-profile biotech leader Deborah Dunsire takes the helm at XTuit, focused on cancer and fibrosis

9 years ago

Biotech spinout grabs $46M round, jumps straight into PhIII with a drug/device combo for rare lung condition

9 years ago

A CRISPR/Cas9 startup launches on the R&D frontier, working on a one-time fix for Duchenne MD

9 years ago

Going big: Biotech vets blast off with Arrakis on a new journey of RNA exploration

9 years ago

PMV Pharma gets a whopping $74M round to test a new p53 drug in humans

9 years ago

With an extra $25M in hand, Dauntless maps the next stage of growth for the pipeline

9 years ago

Versant gambles $20 million on a UCSD spinout focused on NASH and fibrosis

9 years ago

Surrozen grabs $33M, joins startups looking to spark a comeback in regenerative med

9 years ago

After winning an early deal on XO1, the virtual biotech gang gets back together for SuperX

9 years ago

Malin backs another microbiome upstart as Artizan breaks out of ‘covert’ role

9 years ago

Celgene vet Daniel takes a startup role at Vividion, with $50M in hand for platform construction

9 years ago

An upstart immunotherapy biotech emerges from stealth mode with big love for Kendall Square

9 years ago

Eli Lilly, Novartis back a $26M round for Cavion’s work on neurological diseases

9 years ago

Ex-Biogen chief George Scangos to spearhead a Gates-backed startup with big plans to fight infectious diseases

9 years ago

An upstart jumps almost overnight from preclinical to PhI with a $35M Takeda deal and a buyout option

9 years ago

Another Langer-backed biotech breaks out of stealth mode, aims for the clinic with hearing loss therapy

9 years ago

Neon Therapeutics bags a $70M round for early-stage neoantigen research

9 years ago

Medigene spins out AAV tech to a new biotech upstart in Sweden

9 years ago

Shanghai biotech upstart raises $50M, bags antibody discovery group and ramps up Boston unit

9 years ago

Armed with $55M in Third Rock cash, Goldfinch Bio sets out to build a kidney disease pipeline

9 years ago

Pfizer bankrolls an oncolytics biotech upstart with an eye on a future buyout

9 years ago

First page Previous page 70 71 727374 Next page Last page